Trehalose-6, 6′-dibehenate inhibits lipopolysaccharide-induced NF-κB activation via PLC-γ1-PKC-ERK signaling and promotes M2 microglial polarization

Wan-Wan Lin
DOI: https://doi.org/10.4049/jimmunol.198.supp.129.14
2017-05-01
The Journal of Immunology
Abstract:Abstract Activation of microglia triggers a robust amount of pro-inflammatory cytokines, which are involved in the pathogenesis of central nervous system tuberculosis (CNS-TB). The mycobacterial cord factor (Trehalose-6, 6-dimycolate [TDM]), and its synthetic analogue Trehalose-6, 6-dibehenate (TDB) bind to C-type lectin receptors Mincle to activate macrophages and dendritic cells via the Syk/Card9 pathway. However, there are no studies have been conducted to determine the effect of TDB on inflammatory responses in microglia and its underlying signalling pathways. Here using BV2 microglial cells we found that TDB can inhibit NO production, iNOS, pro-IL-1β, and the pro-inflammatory gene expression of TNF-a, pro-IL-1β, IL-6, Mincle, IFNb and MIP2 in LPS-stimulated BV-2 microglial cells. TDB-induced ERK-1/2 activation in LPS-activated microglial cells, whereas TDB had no effect on p38 and JNK phosphorylation induced by LPS. Interestingly, TDB suppressed LPS-induced NF-κB nuclear translocation but did not affect the IKK activity, and these actions were reversed by ERK inhibitor. In addition, TDB caused PLC-γ1 and PKC activation in BV-2 cells, and the TDB-mediated ERK upregulation could be attenuated by PLC-γ1 and PKC inhibitors. TDB also induced AMPK activation via calcium/CaMKK dependent pathway. Moreover, TDB induced M2 gene expression in LPS-stimulated BV-2 cells, and this action was prevented by the AMPK inhibitor, indicating that AMPK activation participates in TDB-mediated M2 polarisation effects. Therefore, TDB may have therapeutic potential for mitigating microglia-mediated neuroinflammation.
immunology
What problem does this paper attempt to address?